Silo Pharma, Inc. (SILO) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Silo Pharma, Inc. is a developmental-stage biopharmaceutical and cryptocurrency company. Its primary therapeutic focus includes developing novel treatments for PTSD, stress-induced anxiety, fibromyalgia, and CNS diseases (specifically programs SPC-15, SP-26, SPC-14, and SPU-16). In August 2025, the Company launched a cryptocurrency treasury strategy, acquiring digital assets such as Bitcoin, Ethereum, and Solana.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $18,025 | $18,025 | $54,076 | $54,076 |
| Net Loss | $(1,110,438) | $(928,814) | $(3,346,168) | $(2,662,260) |
| Loss Per Share (Basic/Diluted) | $(0.12) | $(0.22) | $(0.50) | $(0.78) |
| Cash and Cash Equivalents | $3,917,627 (as of Sept 30, 2025) | |||
| Short-Term Investments | $1,948,579 (as of Sept 30, 2025) | |||
| Working Capital | $5,456,030 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(18,610,859) (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased to $3.52 million for the nine months ended Sept 30, 2025, compared to $2.94 million in the prior year period. This 20% increase was driven primarily by higher Research and Development (R&D) costs ($1.85M vs $1.29M) and increased compensation expenses due to stock-based compensation ($64,712 recognized in 2025 vs $0 in 2024).
- R&D Non-Cash Expense: A significant non-cash R&D expense of $518,225 was recorded in Q3 2025 related to the issuance of 750,000 shares of common stock to acquire software assets (r2crypto.com) for the Company's cryptocurrency strategy.
- Cost of Revenues: Cost of revenues increased to $23,606 for the nine months ended Sept 30, 2025, from $4,378 in the prior year. This increase is attributed to the accelerated amortization of license fees following the termination of the Master License Agreement with the University of Maryland, Baltimore, and the establishment of a new option agreement expiring March 31, 2026.
- Other Income: Other income decreased to $147,970 for the nine months ended Sept 30, 2025, from $230,082 in the prior year, primarily due to lower interest and dividend income and an unrealized loss on crypto assets of $2,690.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash ($3.9M) and short-term investments ($1.9M) are sufficient to meet obligations for at least twelve months. The positive working capital mitigates historical going concern doubts.
- Capital Raising: Subsequent to the reporting period (October 1, 2025), the Company closed a registered direct offering raising gross proceeds of $2.5 million (net proceeds of $2.15 million) to fund working capital and general corporate purposes.
- Strategic Shift: The Company has formally adopted a cryptocurrency treasury strategy, holding approximately $72,000 in crypto assets as of Sept 30, 2025, and established a Crypto Advisory Board.
- Nasdaq Compliance: The Company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00). It has until December 24, 2025, to regain compliance, potentially via a reverse stock split.
- Risks: Significant risks include the volatility of digital asset prices, regulatory uncertainty regarding the classification of digital assets as securities (potential Investment Company Act implications), and the failure to achieve clinical milestones for its biopharmaceutical pipeline.
Investor Verification Checklist
- Cash Runway: Verify the impact of the October 2025 capital raise on the Company's 12-month liquidity projection.
- Nasdaq Status: Monitor the Company's ability to regain compliance with the $1.00 minimum bid price by December 24, 2025, to avoid delisting.
- Crypto Strategy Execution: Assess the valuation and custody risks associated with the new cryptocurrency treasury strategy and the potential for unrealized losses to impact future earnings.
- R&D Milestones: Track progress on the SPC-15 IND submission (targeted for 2026) and the status of the new option agreement with the University of Maryland, Baltimore.
- Dilution: Review the impact of recent warrant exercises and the October 2025 offering on total share count and per-share value.